Fulcrum Therapeutics Posts $0.25 Q1 Loss, Plans H2 2026 Pociredir Trial
Fulcrum posted a Q1 net loss of $18.9 million ($0.25/share), beating the $0.30/share forecast, and its shares rose 2.81% pre-market. The company highlighted strong fetal hemoglobin induction from pociredir, plans a H2 2026 registration-enabling trial, and holds $333.3 million cash runway into 2029.
1. Q1 Financial Performance
Fulcrum reported a net loss of $18.9 million, or $0.25 per share, outperforming the $0.30 per share loss forecast. Research and development expenses rose to $14.1 million from $13.4 million, while general and administrative costs increased to $8.1 million from $7.0 million year-over-year.
2. Clinical Progress for Pociredir
The company highlighted strong induction of fetal hemoglobin and improvements in hemolysis and anemia markers for pociredir. Fulcrum dosed the first participant in an open-label, long-term safety and durability study and aims to launch a registration-enabling trial in the second half of 2026, pending FDA feedback.
3. Cash Position and Runway
Fulcrum closed the quarter with $333.3 million in cash, cash equivalents, and marketable securities, down from $352.3 million at the end of 2025. Management expects existing capital resources to support operations through 2029.
4. CFO Transition
Chief Financial Officer Alan Musso intends to retire later this year and will remain in his role until a successor is appointed, ensuring continuity in financial leadership.